Healthcare / BiotechnologyKSE
$483.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $674.3M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$57.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.4%
↓Gross Margin
24.5%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.8%
FCF CAGR
—
FCF margin
-13.7%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $29.40B · net income $-13.19B · FCF $-4.04B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29.40B | $29.40B | $28.01B | $28.82B | $26.28B |
| Net Income | $-13.19B | $-13.19B | $12.87B | $-12.42B | $34.20B |
| EBITDA | $-11.02B | $-11.02B | $15.61B | $-9.25B | $997.2M |
| EPS | -111.00 | -111.00 | 109.00 | -105.00 | 288.00 |
| Gross Margin | 24.5% | 24.5% | 34.2% | 34.1% | 34.3% |
| Operating Margin | -10.5% | -10.5% | 15.9% | 12.0% | -14.4% |
| Net Margin | -44.9% | -44.9% | 46.0% | -43.1% | 130.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.04 | 0.01 | 0.09 |
| Current Ratio | 1.80 | 1.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.04B | $-4.04B | $2.83B | $674.3M | $140.5M |
| Returns | |||||
| ROE | -18.4% | -18.4% | 15.1% | -17.4% | 41.1% |
| Valuation | |||||
| P/E | — | — | 5.26 | — | 3.17 |
| EV/EBITDA | — | — | 4.14 | — | 86.17 |
| P/B | 0.80 | 0.80 | 0.80 | 1.05 | 1.30 |
| Growth & Yield | |||||
| Revenue Growth | 5.0% | 5.0% | -2.8% | 9.7% | — |
| EPS Growth | -201.8% | -201.8% | 203.8% | -136.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-63.9%
Start / end P/E
n/dx → n/dx
EPS bridge
109.00 → -111.00
Residual
-63.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.